RxDoctor Payments Data

Ronaldo Supena

Infectious Disease · Detroit, MINPI 1275576886

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 96.9% of the total across 683 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by Viiv Healthcare Company at 43.2% of the total. Reporting peaked in 2023 at $2,800 and has fallen 53.2% since, to $1,310 in 2025. Among infectious disease clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$14,493in general payments, 2019–2025

Across 683 payments — averaging $21.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$6K
  • Gilead$4K
  • Merck$2K
  • Janssen Products, LP$1K
  • Johnson & Johnson$934
  • Pfizer$176
  • plus $342 from 13 others

What the payments were for

  • Food & beverage$14,04397%
  • Education$4503%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,493 in reported general payments places this provider in the 90th percentile of 257 infectious disease providers in Michigan.

See all infectious disease providers in Michigan

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala84$337,837
JulucaDolutegravir/Rilpivirine57$190,721
GenvoyaElviteg/Cob/Emtri/Tenof Alafen41$170,799
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf35$156,778
CabenuvaCabotegravir/Rilpivirine14$95,576
DovatoDolutegravir Sodium/Lamivudine33$95,267
OdefseyEmtricitab/Rilpiviri/Tenof Ala20$76,637
TriumeqAbacavir/Dolutegravir/Lamivudi17$58,844
DelstrigoDoravirine/Lamivu/Tenofov Diso15$42,089
TivicayDolutegravir Sodium16$35,185
PrezcobixDarunavir/Cobicistat14$33,133
Acetaminophen-CodeineAcetaminophen With Codeine35$932
Albuterol Sulfate HfaAlbuterol Sulfate27$889
Ventolin HfaAlbuterol Sulfate15$788
Pravastatin Sodium94$566

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya$3,835$508,637125 claims
Viiv Healthcare CompanyJuluca, Cabenuva, Dovato, Triumeq, Tivicay$6,260$475,592137 claims
Janssen Products, LPSymtuza$1,197$156,77835 claims
MerckDelstrigo$1,749$42,08915 claims
Johnson & JohnsonPrezcobix$934$33,13314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 257 infectious disease providers in Michigan.

Other infectious disease in Detroit

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →